Business Context and Reporting Period
This Form 8-K is filed by Xcyte Therapies, Inc. (not Bio Green Med Solution, Inc.) for the reporting period of November 1, 2004. The filing documents a material modification to the rights of security holders and the closing of a public offering of preferred stock.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial event reported is the public offering of 2,990,000 shares of 6% Convertible Exchangeable Preferred Stock at an initial purchase price of $10 per share.
Material Changes
- Capital Structure: The Company established a new class of 6% Convertible Exchangeable Preferred Stock via a Certificate of Designations filed with the Delaware Secretary of State.
- Dividend Restrictions: Payment of dividends on Common Stock is now restricted unless cumulative dividends on the Preferred Stock are paid or set aside.
- Liquidation Preference: Each share of Preferred Stock holds a liquidation preference equal to the initial $10 purchase price.
- Offering Status: The public offering of 2,990,000 shares was announced as closed on November 3, 2004.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the structural changes to shareholder rights. The primary contingency noted is the priority of Preferred Stock dividends and liquidation preferences over Common Stock.
Investor Verification Checklist
- Verify the total capital raised from the 2,990,000 shares of Preferred Stock (implied $29.9 million based on $10/share).
- Review the full Registration Statement (Form S-1, No. 333-119585) for detailed terms of the Convertible Preferred Stock.
- Confirm the impact of the new dividend restrictions on existing Common Stockholders.
- Check subsequent filings for the conversion terms and exercise price of the Preferred Stock.